DDInter1233 DDInter741
Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma and is used off-label for the management of Cushing's syndrome.
Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals. Flibanserin's mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.
Mitotane {u} (Compound) resembles {v} (Compound) Chlorpheniramine
Chlorpheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flibanserin
Mitotane {u} (Compound) resembles {v} (Compound) Chlorpheniramine
Chlorpheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Rolapitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flibanserin
Mitotane {u} (Compound) downregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Flibanserin
Mitotane {u} (Compound) resembles {v} (Compound) Carbinoxamine
Carbinoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenindamine
Phenindamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flibanserin
Mitotane {u} (Compound) upregulates {v} (Gene) ADGRE5
ADGRE5 {u} (Gene) is downregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Flibanserin
Mitotane {u} (Compound) downregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is upregulated by {v} (Compound) Clemastine
Clemastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flibanserin
Mitotane {u} (Compound) resembles {v} (Compound) Carbinoxamine
Carbinoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxylamine
Doxylamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flibanserin
Mitotane {u} (Compound) resembles {v} (Compound) Chlorpheniramine
Chlorpheniramine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxylamine
Doxylamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flibanserin
Mitotane {u} (Compound) causes {v} (Side Effect) Encephalopathy
Encephalopathy {u} (Side Effect) is caused by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Flibanserin
Mitotane {u} (Compound) upregulates {v} (Gene) ADGRE5
ADGRE5 {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flibanserin
Mitotane (Compound) resembles Chlorpheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Mitotane (Compound) resembles Chlorpheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Mitotane (Compound) downregulates HMGCR (Gene) and HMGCR (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Flibanserin
Mitotane (Compound) resembles Carbinoxamine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Mitotane (Compound) upregulates ADGRE5 (Gene) and ADGRE5 (Gene) is downregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Flibanserin
Mitotane (Compound) downregulates HMGCR (Gene) and HMGCR (Gene) is upregulated by Clemastine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Mitotane (Compound) resembles Carbinoxamine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Mitotane (Compound) resembles Chlorpheniramine (Compound) and Chlorpheniramine (Compound) resembles Doxylamine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Mitotane (Compound) causes Encephalopathy (Side Effect) and Encephalopathy (Side Effect) is caused by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Flibanserin
Mitotane (Compound) upregulates ADGRE5 (Gene) and ADGRE5 (Gene) is upregulated by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin